Warning letter
Ameriderm Laboratories, Ltd.: warning letter of Dec 2, 2013
FDA warning letter 406166 · New Jersey District Office
Key facts
| Reference number | 406166 |
|---|---|
| Company | Ameriderm Laboratories, Ltd. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Dec 2, 2013 |
| Posted date | Dec 2, 2013 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 211.22(b), 211.67(b), 211.84(d)(2), 211.100(a), 211.100(b), 211.160(b) |
| Inspection city | Paterson |
| Inspection ZIP | 07503 |
| Inspection start date | Feb 1, 2013 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: